Data / Form D filings / Origin Life Sciences, Inc.
Origin Life Sciences, Inc.: Form D filings
Origin Life Sciences, Inc., a biotechnology company in Princeton, NJ, filed 6 Form D notices with the SEC between 2013 and 2023. The latest, on October 17, 2023, reports $51,000 sold of a $5 million offering to 2 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 2 RESEARCH WAY, THIRD FLOOR, Princeton, NJ, 08540
- Phone
- (609) 250-6000
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1573901
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Oct 17, 2023 | New notice | $5,000,000 | $51,000 | $4,949,000 | 2 | Aug 18, 2023 | sec.gov |
| Jun 22, 2023 | Amendment | $850,000 | $659,600 | $190,400 | 6 | May 30, 2023 | sec.gov |
| Jun 1, 2023 | New notice | $850,000 | $500,000 | $350,000 | 1 | May 30, 2023 | sec.gov |
| Sep 7, 2022 | New notice | $5,000,000 | $500,000 | $4,500,000 | 7 | Jun 30, 2022 | sec.gov |
| May 15, 2017 | New notice | $22,500,000 | $1,332,100 | $21,167,900 | 32 | Jan 6, 2017 | sec.gov |
| Apr 8, 2013 | New notice | $2,500,000 | $500,000 | $2,000,000 | 1 | Mar 22, 2013 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Michael David Preston | Executive Officer, Director | |
| Jerome Boda Korten | Director | |
| Victor David Micati | Director | |
| David David Dantzker | Executive Officer, Director | |
| John David Fernandes | Executive Officer | |
| Anthony David Brampton | Director |
Other biotechnology companies in New Jersey that filed recently
- Ensho Therapeutics, Inc. $7.3 million · Oct 15, 2026
- Xenon Ophthalmics Inc $3.3 million · Oct 6, 2026
- LISATA THERAPEUTICS, INC. $351.9 million · Oct 2, 2026
- Bullseye Biodevices, Inc. $1.3 million · Aug 10, 2026
- Hepion Pharmaceuticals, Inc. $3.1 million · Aug 5, 2026
Every Form D from the week of Oct 16, 2023 · All recent filings in New Jersey · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Origin Life Sciences, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.